

**IN THE SPECIFICATION:**

**Please replace the paragraph beginning at Page 31, line 10 with the following rewritten paragraph:**

**--BRIEF DESCRIPTION OF THE DRAWINGS**

Figures 1A-1F show the nucleotide (SEQ ID NO:1) and predicted amino (SEQ ID NO:2) sequence of murine NR4. The untranslated region is shown in lower case and the translated region in upper case. The conventional one-letter code for amino acids is employed, potential asparagine linked glycosylation sites are underlined and the conserved cysteine residues and WSXWS (SEQ ID NO: 9) motif of haemopoietin receptor family members are shown in bold. The predicted signal sequence is underlined in bold while the transmembrane domain is underlined with dashes. The sequence shown is a composite derived from the analysis of 8 cDNA clones derived from 3 libraries. The 5'-end of the sequence (nucleotides -60 to 351) is derived from a single cDNA clone but is also present in genomic DNA clones that have been isolated. Boxed region – typical haemopoietin receptor domain, amino acids 118-340.--

**Please replace the paragraph beginning at Page 31, line 27 with the following rewritten paragraph:**

--Figures 3A-3B depict saturation isotherms of  $^{125}\text{I}$ -IL-13 and  $^{125}\text{I}$ -IL-4 binding; saturation isotherms depicted as Scatchard plots of IL-4( $^{\circ}$ ) and IL-13( $\bullet$ ) binding to COS cells expressing the IL-13R $\alpha$ (NR4) (Figure 3A), CTLL cells (Figure 3B) and CTLL cells expressing the IL-13R $\alpha$ (NR4) (Figure 3C). Data have been normalized to  $1 \times 10^4$  COS cells and  $1 \times 10^6$  CTLL cells and binding was carried out on ice for 2 to 4 hours.--

**Please replace the paragraph beginning at Page 32, Line 3 with the following rewritten**

**paragraph:**

12 cont.  
--Figures 4A-4D show specificity of IL-4 and IL-13 binding; the ability of IL-4(°) and IL-13(•) to compete for <sup>125</sup>I-IL-13 binding to COS cells expressing the IL-13Rα(NR4) (Figure 4A) and CTLL cells expressing the IL-13Rα (NR4) (Figure 4C) or to compete for <sup>125</sup>I-IL-4 binding to CTLL cells (Figure 4) and CTLL cells expressing the IL-13Rα(NR4) (Figure 4). Binding was carried out at 4°C for 2 to 4 hours and the data expressed as a percentage of the specific binding observed in the absence of a competitor (Δ).--

**Please replace the paragraph beginning at Page 32, line 10 with the following rewritten**

**paragraph:**

--Figures 5A-5B show factor dependent proliferation of cells expressing NR4. Two hundred CTLL cells (Figure 5) or CTLL cells (Figure 5) expressing the IL-13Rα (NR4) were incubated in the absence of cytokine or with various concentrations of IL-2 (□), IL-4(°) or IL-13 (•). After 48 hours viable cells were counted and data were expressed as a percentage of the number of viable cells observed with a maximal concentration of IL-2.--

**Please replace the paragraph beginning at Page 32, line 3 with the following rewritten**

**paragraph:**

13  
--Figures 7A-7J show the nucleotide and corresponding amino acid sequence of murine SEQ ID NOS: 1 and 2, respectively) and human (SEQ ID NOS: 3 and 4, respectively) NR4 (IL-13Rα) genes. The nucleotide and predicted amino acid sequence of human (H) and murine (M) IL-13Rα(NR4) were aligned by eye, with gaps (-) inserted to optimize the alignment. The numbering is for the murine clone, nucleotides that form part of the coding region are shown in upper case, whilst those of the untranslated regions are shown in lower case. Amino acids

identical between the predicted murine and human proteins are indicated by (\*). DNA encoding the murine signal sequence is underlined, with A26 or T27 being the predicted first amino acid of the mature protein.--

**Please amend the paragraph beginning at page 33, line 12, as follows:**

--Figure 10 is a representation of the N-terminal amino acid sequence of murine NR4 (SEQ ID NOS: 10 and 11).--

**Please amend the paragraph beginning at page 37, line 3, as follows:**

--A library was constructed  $\lambda$ ZAP II using *ApoI* digested genomic DNA from embryonal stem cells and screened with a pool of  $^{32}$ P-labelled oligonucleotides encoding the amino acid sequence Trp-Ser-Asp-Trp-Ser (SEQ ID NO: 12) found in many members of the haemopoietin receptor family. One hybridising bacteriophage clone was found to contain a sequence that appeared to encode part of a novel member of the haemopoietin receptor family. This receptor was given the operational name NR4. The sequence of the genomic clone was used to isolate cDNAs encoding NR4 from WEHI-3B cell, peritoneal macrophage, bone marrow, skin and kidney libraries. A composite of the nucleotide sequence (SEQ ID NO: 1) and predicted amino acid sequence (SEQ ID NO: 2) of these cDNAs is shown in Figure 1. The NR4 cDNA is predicted to encode for a protein of 424 amino acid residues, containing a putative signal sequence and transmembrane domain. The extracellular region of the protein contained an immunoglobulin-like domain (amino acids 27-117), in addition to a typical haemopoietin receptor domain (amino acids 118-340) which includes four conserved cysteine residues and the characteristic Trp-Ser-Asp-Trp-Ser motif (Figure; in bold as WSXWS). The cytoplasmic tail of the new receptor was 60 amino acids in length.--